Portal de Periódicos da CAPES

Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards) registry

2010; Oxford University Press; Volume: 32; Issue: 2 Linguagem: Inglês

10.1093/eurheartj/ehq261

1522-9645

Hélène Eltchaninoff, Alain Prat, Martine Gilard, Alain Leguerrier, Didier Blanchard, G Fournial, Bernard Iung, Patrick Donzeau‐Gouge, C. Tribouilloy, Jean-Louis Debrux, Alain Pavie, Pascal Guéret, P. Leprince, Farzin Beygui, J.-P. Collet, D. Himbert, Patrick Nataf, A. Vahanian, Thierry Lefèvre, Mauro Romano, Hélène Eltchaninoff, Pierre‐Yves Litzler, Jean Paul Bessou, Alain Cribier, Jean Fajadet, Didier Carrié, Pierre Berthoumieu, Nicolas Dumonteil, G Fournial, Emmanuel Teíger, Jean Luc Dubois Randé, Matthias Kirsch, Didier Blanchard, J.-N. Fabiani, Arnaud Sudre, Thomas Modine, Pierre Dos Santos, Jean-Philippe Guibaud, X. Roques, Martine Gilard, J Boschat, Eric Bezon, François Schiele, Sidney Chocron, Nicolas Méneveau, Jean‐Pierre Bassand, Gilles Rioufol, J.-F. Obadia, Ashok Tirouvanziam, J Roussel, D Crochet, F. Collard, Jacques Bonnet, Th o Damien Cuisset, Jean‐Eric Wolf, O. Bouchot, Pascal Guéret, Alain Pavie, Didier Blanchard, Jean-Louis Debrux, Patrick Donzeau‐Gouge, Hélène Eltchaninoff, Martine Gilard, Bernard Iung, Alain Leguerrier, Alain Prat, C. Tribouilloy, K. Chevreul,

Aortic Disease and Treatment Approaches

Transcatheter aortic valve implantation is a therapeutic alternative for high-surgical-risk patients with severe symptomatic aortic stenosis. Two models of prosthesis are currently commercialized in France, which can be implanted either via a transarterial or a transapical approach. The aim of the study was to evaluate in a national French registry the early safety and efficacy of transcatheter aortic valve replacement (AVR) using either the Edwards SAPIEN™ or CoreValve™ in high-surgical-risk patients with severe aortic stenosis. The multicentre national registry was conducted in 16 centres between February 2009 and June 2009, under the authority of the French Societies of Cardiology and Thoracic and Cardio-Vascular Surgery. The primary endpoint was mortality at 1 month. Two hundred and forty-four high-surgical-risk patients (logistic EuroSCORE ≥20%, STS ≥10%, or contra-indication to AVR) were enrolled. Mean age was 82 ± 7 years and 43.9% were female. Edwards SAPIEN and CoreValve were implanted in 68 and 32% of patients, respectively. The approaches used were transarterial (transfemoral: 66%; subclavian: 5%) or transapical in 29%. Device success rate was 98.3% and 30-day mortality was 12.7%. Severe complications included stroke (3.6%), tamponade (2%), acute coronary occlusion (1.2%), and vascular complications (7.3%). Pacemaker was required in 11.8%. At 1 month, 88% of patients were in NYHA class II or less. This prospective registry reflects the real-life experience of transcatheter aortic valve implantation in high-risk elderly patients in France. The early results are satisfactory in terms of feasibility, short-term haemodynamic and functional improvement, and safety. Longer term follow-up will be further assessed.